Who is sponsoring NCT00154271?

NCT00154271 is sponsored by Novartis.

What condition does NCT00154271 study?

NCT00154271 studies Hypertension.

What drugs are being tested in NCT00154271?

Interventions: Valsartan, Valsartan HCT.

What is the status of NCT00154271?

NCT00154271 is currently COMPLETED.

Last reviewed 2011-11-07 · How we verify

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

NCT00154271 Phase 4 COMPLETED

The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension. Additionally, the study examines the effects of blood pressure reduction on the levels of high sensitivity hsCRP. Although the main goal is to determine the overall effect of blood pressure reduction on hsCRP levels, analysis will also evaluate whether an aggressive antihypertensive regimen is more effective than a moderate one in reducing hsCRP levels.

Details

Lead sponsor	Novartis
Phase	Phase 4
Status	COMPLETED
Enrolment	1677
Start date	2004-01
Completion	2005-06

Conditions

Hypertension

Interventions

Valsartan, Valsartan HCT

Primary outcomes

Change from baseline to Week 6 in mean sitting blood pressure (SD)
Change from baseline to Week 12 in median plasma hsCRP
Change from baseline to Week 6 in median plasma hsCRP